Bone loss in survival motor neuron (Smn-/- SMN2) genetic mouse model of spinal muscular atrophy

被引:58
|
作者
Shanmugarajan, Srinivasan [1 ]
Tsuruga, Eichi [1 ]
Swoboda, Kathryn J. [3 ]
Maria, Bernard L. [1 ]
Ries, William L. [2 ]
Reddy, Sakamuri V. [1 ]
机构
[1] Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Coll Dent Med, Charleston, SC 29425 USA
[3] Univ Utah, Sch Med, Dept Pediat, Div Neurol, Salt Lake City, UT USA
基金
美国国家卫生研究院;
关键词
spinal muscular atrophy; osteoclast; RANK ligand; survival motor neuron; mouse model; OSTEOCLAST FORMATION; BINDING-PROTEIN; IDENTIFICATION; MECHANISMS; FRACTURES; MICE; INTERACTS; PRODUCT; VARIANT;
D O I
10.1002/path.2566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spinal muscular atrophy (SMA) is characterized by degenerating lower motor neurons and an increased incidence of congenital bone fractures. Survival motor neuron (SMN) levels are significantly reduced due to deletions/mutations in the telomeric SMN1 gene in these patients. We utilized the Smn(-/-) SMN2 mouse model of SMA to determine the functional role for SMN in bone remodelling. mu CT analysis of lumber vertebrae, tibia and femur bones from SMA mice revealed an osteoporotic bone phenotype. Histological analysis demonstrated a thin porous cortex of cortical bone and thin trabeculae at the proximal end of the growth plate in the vertebrae of SMA mice compared to wild-type mice. Histochemical staining of the vertebrae showed the presence of abundant activated osteoclasts on the sparse trabeculae and on the endosteal surface of the thin cortex in SMA mice. Histomorphometric analysis of vertebrae from SMA mice showed an increased number of osteoclasts. Serum TRAcP5b and urinary NTx levels were elevated, consistent with increased bone resorption in these mice. SMA mice showed a significant decrease in the levels of osteoblast differentiation markers, osteocalcin, osteopontin and osterix mRNA expression; however, there were no change in the levels of alkaline phosphatase expression compared to WT mice. SMA mouse bone marrow cultures revealed an increased rate of osteoclast formation (54%) and bone resorption capacity (46%) compared to WT mice. Pre-osteoclast cells from SMA mice showed constitutive up-regulation of RANK receptor signalling molecules critical for osteoclast differentiation. Our results implicate SMN function in bone remodelling and skeletal pathogenesis in SMA. Understanding basic mechanisms of SMN action in bone remodelling may uncover new therapeutic targets for preventing bone loss/fracture risk in SMA. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 50 条
  • [31] Defects in neuromuscular junction remodelling in the Smn2B/- mouse model of spinal muscular atrophy
    Murray, Lyndsay M.
    Beauvais, Ariane
    Bhanot, Kunal
    Kothary, Rashmi
    NEUROBIOLOGY OF DISEASE, 2013, 49 : 57 - 67
  • [32] The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy
    Arnold, W.
    McGovern, Vicki L.
    Sanchez, Benjamin
    Li, Jia
    Corlett, Kaitlyn M.
    Kolb, Stephen J.
    Rutkove, Seward B.
    Burghes, Arthur H.
    NEUROBIOLOGY OF DISEASE, 2016, 87 : 116 - 123
  • [33] Hyperexcitability precedes motoneuron loss in the Smn2B/- mouse model of spinal muscular atrophy
    Quinlan, K. A.
    Reedich, E. J.
    Arnold, W. D.
    Puritz, A. C.
    Cavarsan, C. F.
    Heckman, C. J.
    DiDonato, C. J.
    JOURNAL OF NEUROPHYSIOLOGY, 2019, 122 (04) : 1297 - 1311
  • [34] Effect of genetic background on the phenotype of the Smn2B/- mouse model of spinal muscular atrophy
    Eshraghi, Mehdi
    McFall, Emily
    Gibeault, Sabrina
    Kothary, Rashmi
    HUMAN MOLECULAR GENETICS, 2016, 25 (20) : 4494 - 4506
  • [35] The gene copy ratios of SMN1/SMN2 in Japanese carriers with type I spinal muscular atrophy
    Tran, TD
    Kroepfl, T
    Saito, M
    Nagura, M
    Ichiseki, H
    Kubota, M
    Toda, T
    Sakakihara, Y
    BRAIN & DEVELOPMENT, 2001, 23 (05) : 321 - 326
  • [36] Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy
    Cobb, Melissa S.
    Rose, Ferril F.
    Rindt, Hansjoerg
    Glascock, Jacqueline J.
    Shababi, Monir
    Miller, Madeline R.
    Osman, Erkan Y.
    Yen, Pei-Fen
    Garcia, Michael L.
    Martin, Brittanie R.
    Wetz, Mary J.
    Mazzasette, Chiara
    Feng, Zhihua
    Ko, Chien-Ping
    Lorson, Christian L.
    HUMAN MOLECULAR GENETICS, 2013, 22 (09) : 1843 - 1855
  • [37] Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
    Winkelsas, Audrey M.
    Grunseich, Christopher
    Harmison, George G.
    Chwalenia, Katarzyna
    Rinaldi, Carlo
    Hammond, Suzan M.
    Johnson, Kory
    Bowerman, Melissa
    Arya, Sukrat
    Talbot, Kevin
    Wood, Matthew J.
    Fischbeck, Kenneth H.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 23 : 731 - 742
  • [38] Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy
    Ando, Shiori
    Suzuki, Shunya
    Okubo, Shoichi
    Ohuchi, Kazuki
    Takahashi, Kei
    Nakamura, Shinsuke
    Shimazawa, Masamitsu
    Fuji, Koji
    Hara, Hideaki
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene
    Hao, Le T.
    Burghes, Arthur H. M.
    Beattie, Christine E.
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [40] Simultaneous quantification of SMN1 and SMN2 copy numbers by MALDI-TOF mass spectrometry for spinal muscular atrophy genetic testing
    Jin, Weijiang
    Yang, Zhengquan
    Tang, Xiaojun
    Wang, Xiuchao
    Huang, Yaxin
    Hui, Chenmin
    Yao, Jiaming
    Luan, Ju
    Tang, Shaohua
    Wu, Shengnan
    Jin, Shengnan
    Ding, Chunming
    CLINICA CHIMICA ACTA, 2022, 532 : 45 - 52